Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S covers the month of August 2024. The report details corporate actions regarding share capital increases and the amendment of the Company's Articles of Association.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. Specific capital transaction data includes:
- Share Capital Increase (July 31, 2024): Nominal DKK 1,640,000 from the exercise of pre-funded warrants, bringing total share capital to nominal DKK 55,750,546.
- Share Capital Increase (August 12, 2024): Nominal DKK 10,000 from the sale of 1,000 ADSs, bringing total share capital to nominal DKK 55,760,546.
- ATM Offering Proceeds: Approximately $2,500 net proceeds from the sale of 1,000 ADSs at an average price of $2.56 per ADS.
Material Changes
Material changes reported in this period are limited to corporate structure and capitalization:
- Exercise of pre-funded warrants for 1,640,000 ordinary shares at an exercise price of $1.4537 per ADS.
- Completion of an at-the-market (ATM) offering of 1,000 ADSs under the Capital Demand Sales Agreement with Jones Trading Institutional Services LLC.
- Amendments to the Articles of Association to reflect the aforementioned capital increases.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It focuses solely on the execution of capital transactions and the resulting legal amendments to the Articles of Association.
Investor Verification Checklist
- Verify the remaining number of pre-funded warrants (2,229,000 ADSs) and their exercise terms.
- Confirm the impact of the nominal share capital increases on the total number of outstanding shares.
- Review the full Articles of Association (Exhibit 1.1) for any other structural changes.
- Note that the ATM offering generated minimal proceeds ($2,500) relative to the company's overall capitalization.